2025-02-12
Financial Times Front Page 12th of February 2025
Trades associated with Trump have encountered setbacks as the dollar weakens and bond yields dip, inflation worries subside, and investors shift focus to broader economic consequences.
2025-02-11
Financial Times Front Page 11th of February 2025
According to a leading BoE figure, anticipated job losses may temper inflation by curbing consumer demand, prompting a watchful stance over future rate decisions.
2025-02-10
Financial Times Front Page 10th of February 2025
US and China appear poised for a heightened trade conflict as retaliatory tariffs on billions of dollars’ worth of American goods raise international economic concerns, prompting warnings of further escalation.
2025-02-07
Financial Times Front Page 7th of February 2025
The Bank of England has halved its growth outlook, triggering a rate cut that boosts the FTSE 100 to record levels, while sterling slides and concerns of economic stagnation pose a setback for Reeves.
2025-02-06
Financial Times Front Page 6th of February 2025
Trump’s plan for Gaza draws global condemnation from Western allies, causing outrage among Arabs and Europeans and sparking fears for the West Bank.
2025-02-05
Financial Times Front Page 5th of February 2025
China aims to gain leverage in talks with the Trump administration by recommencing probes into major US technology firms, prompting cautious scrutiny from Western governments.
2025-02-04
Financial Times Front Page 4th of February 2025
Following discussions between Sheinbaum and Trump, tariffs on Mexican goods have been temporarily suspended, leading to a rebound in market confidence and easing tension regarding border policy.
2025-02-03
Financial Times Front Page 3rd of February 2025
Businesses are pushing back against trade measures that are expected to increase inflationary pressures and raise prices for consumers, with concerns over economic impact and supply chain disruptions.
2025-02-01
Financial Times Front Page 1st of February 2025
AstraZeneca has decided to abandon its £450 million vaccine manufacturing facility project, following disagreements over state support and raising concerns about potential impacts on the broader growth strategy.









